- ENGUARD PHX CARDIOPLEGIA HEAT EXCHANGER (K991137) — FDA 510 (k . . .
The EnGuard™ PHX Cardioplegia Heat Exchanger is a medical device used during coronary bypass procedures to provide myocardial protection or controlled heart arrest
- ENGUARD PHX CARDIOPLEGIA HEAT EXCHANGER 510(k) K991137 - fda. report
FDA report database pages for FDA medical devices, drugs, labels, recalls, product codes, standards, and related public records
- K991137 EnGuardTMM PHX Cardioplegia Heat E - accessdata. fda. gov
Minntech Corporation has provided the above information within the 510(k) to support the claim that the EnGuardTM PHX Cardioplegia Heat Exchanger is safe and effective when used in accordance
- ENGUARD PHX CARDIOPLEGIA HEAT EXCHANGER - BEUDAMED
FDA 510 (k) clearance for medical device ENGUARD PHX CARDIOPLEGIA HEAT EXCHANGER, FDA class 2, K number K991137 Decision: Substantially Equivalent
- 510 (k) Premarket Notification
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players
- Minntech, Biocor oxygenator and EnGUARD PHX cardioplegia system . . .
Founded in 1985, the company has consistently focused on developing innovative solutions for cardiopulmonary care, particularly through its advanced Biocor oxygenator and the EnGUARD PHX cardioplegia system components
- Minntech-Corp FDA Filings - FDA. report
FDA report database pages for FDA medical devices, drugs, labels, recalls, product codes, standards, and related public records
- Control Panel - EnGuard
EnGuard allows email login access from the United States only, this protects you
- Contact EnGuard | HIPAA Compliant Email Support and Sales
Get in touch with EnGuard's US-based team for sales, support, and general inquiries Real people, no bots, no overseas call centers Monday through Friday
- Minntech to Sell Cardiopulmonary Assets - Med Device Online
Under the terms of the deal, Minntech will sell assets and rights related to its Biocor oxygenator and Enguard Phx cardioplegia system components to LifeStream and will receive $2 5 million in cash at closing and the other $4 7 million over the next two years
|